This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Thymosin, a semipurified extract from the thymus gland that is being tested as a T lymphocyte stimulator, now will be evaluated in the treatment of rheumatoid arthritis.
In what it says are "the first such trials in the United States," George Washington University Medical Center, Washington, DC, is beginning a doubleblind study of approximately 60 patients with adultonset rheumatoid arthritis. They will be divided into two groups receiving thymosin (different dosages) and one group receiving a placebo.
Extracts of thymosin fraction 5, which has been used to treat children with immunodeficiencies, will be administered by injection twice weekly (JAMA [MEDICAL NEWS] 1981;246:205, 1977;237:429-438). The study, sponsored by the National Institutes of Health (NIH), Bethesda, Md, and Hoffmann-La Roche Inc, Nutley, NJ, is expected to last two to three years.
Patients participating must be aged 18 years or older, have had continuous disease activity for at least six months, and have
T-cell stimulator undergoes diverse testing. JAMA. 1982;248(7):807–811. doi:10.1001/jama.1982.03330070005002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: